Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced that the U.S. Patent and Trademark Office (PTO) has issued a Patent Term Adjustment (PTA) extending the patent term by 18 months for its patent No. 9,259,456, titled, "Methods and Compositions for Oral Administration of Proteins". Oramed had previously announced receiving an allowance on the patent. The PTA increases the patent term from the standard 20 years from the date of its earliest non-provisional application to 21 years and 6 months, extending the term through March 2, 2028. The patent addresses Oramed's platform technology which underlies its products, including ORMD-0801, an orally ingestible insulin capsule.
"The U.S. diabetes market is the largest single diabetes market worldwide," stated Oramed CEO Nadav Kidron. "We are very pleased that the U.S. PTO has granted an extension beyond the standard patent term, further enhancing the value of our intellectual property in this market."